Abstract | Background: Methods: This trial was an open-label single arm clinical trial. Ten patients with dysmenorrhea and pelvic pain associated with endometriosis and adenomyosis were enrolled in this trial, and received 40 mg of SR-16234 once daily for 12 weeks. The primary endpoint was the visual analogue scale (VAS) of pelvic pain. The secondary endpoints included dysmenorrhea score, pelvic pain score, objective observations (stiffness of Douglas' pouch, limitation of uterine movement, size of ovarian chocolate cysts, thickness of endometrium, and serum CA125 concentration) and safety. Results: Conclusion:
|
Authors | Tasuku Harada, Ikuko Ohta, Yusuke Endo, Hiroshi Sunada, Hisashi Noma, Fuminori Taniguchi |
Journal | Yonago acta medica
(Yonago Acta Med)
Vol. 60
Issue 4
Pg. 227-233
(12 2017)
ISSN: 0513-5710 [Print] Japan |
PMID | 29434492
(Publication Type: Journal Article)
|